is tirzepatide stronger than semaglutide for weight loss?
A direct human comparison exists, so the answer can stay with the trial rather than mechanism inference.
verdict: greater mean weight reduction in SURMOUNT-5 (direct open-label evidence)
quick answer
SURMOUNT-5 compared maximum tolerated weekly tirzepatide and semaglutide doses for 72 weeks in 751 adults with obesity and no diabetes. Mean weight change was -20.2 percent versus -13.7 percent. The open-label group result does not prescribe an individual choice.
the evidence
The comparison is direct. (supported)
SURMOUNT-5 used an open-label maximum-tolerated comparison in adults with obesity and no diabetes.
The result is population specific. (gap)
The trial average does not transfer to every indication, product, or individual.
Comparison is not prescribing. (risk)
The page reports trial evidence and does not recommend switching products or choosing a dose.
bottom line
The comparative efficacy claim is supported for the SURMOUNT-5 design and population. Product labels, risks, and individual decisions remain separate.
scores
- human trials: 92 · direct open-label head-to-head data
- mechanism: 84 · dual agonism versus GLP-1 alone
- regulatory clarity: 88 · product-specific current labels
- claim boundary: 32 · a group average is not an individual recommendation
keep reading
- full comparison · side-by-side entries
- open tirzepatide entry · dual-agonist record
- open semaglutide entry · GLP-1 benchmark
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.